Hepatitis Drug Development Pipeline Review, 2018

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 7
2 Introduction 8
2.1 Hepatitis Report Coverage 8
2.2 Hepatitis A - Overview 8
2.3 Hepatitis B - Overview 8
2.4 Hepatitis D - Overview 8
2.5 Hepatitis E - Overview 8
3 Therapeutics Development 9
3.1 Hepatitis A 9
3.2 Hepatitis B 12
3.3 Hepatitis D 27
3.4 Hepatitis E 30
4 Therapeutics Assessment 33
4.1 Hepatitis A 33
4.2 Hepatitis B 35
4.3 Hepatitis D 44
4.4 Hepatitis E 49
5 Companies Involved in Therapeutics Development 52
5.1 Hepatitis A 52
5.2 Hepatitis B 54
5.3 Hepatitis D 95
5.4 Hepatitis E 98
6 Dormant Projects 101
6.1 Hepatitis A 101
6.2 Hepatitis B 102
6.3 Hepatitis D 108
6.4 Hepatitis E 108
7 Discontinued Products 109
7.1 Hepatitis B 109
8 Product Development Milestones 110
8.1 Hepatitis B 110
8.2 Hepatitis D 122
8.3 Hepatitis E 131
9 Appendix 132
9.1 Methodology 132
9.2 Coverage 132
9.3 Secondary Research 132
9.4 Primary Research 132
9.5 Expert Panel Validation 132
9.6 Contact Us 133
9.7 Disclaimer 133

List of Tables
1.1 List of Tables
Table 1: Number of Products under Development for Hepatitis A 9
Table 2: Number of Products under Development by Companies, Hepatitis A 10
Table 3: Number of Products under Development by Universities/Institutes, Hepatitis A 11
Table 4: Products under Development by Companies, Hepatitis A 11
Table 5: Products under Development by Universities/Institutes, Hepatitis A 11
Table 6: Number of Products under Development for Hepatitis B 12
Table 7: Number of Products under Development by Companies, Hepatitis B 14
Table 8: Number of Products under Development by Universities/Institutes, Hepatitis B 17
Table 9: Products under Development by Companies, Hepatitis B 18
Table 10: Products under Development by Universities/Institutes, Hepatitis B 26
Table 11: Number of Products under Development for Hepatitis D 27
Table 12: Number of Products under Development by Companies, Hepatitis D 28
Table 13: Number of Products under Development by Universities/Institutes, Hepatitis D 29
Table 14: Products under Development by Companies, Hepatitis D 29
Table 15: Products under Development by Universities/Institutes, Hepatitis D 29
Table 16: Number of Products under Development for Hepatitis E 30
Table 17: Number of Products under Development by Companies, Hepatitis E 31
Table 18: Number of Products under Development by Universities/Institutes, Hepatitis E 32
Table 19: Products under Development by Companies, Hepatitis E 32
Table 20: Products under Development by Universities/Institutes, Hepatitis E 32
Table 21: Number of Products by Stage and Route of Administration, Hepatitis A 33
Table 22: Number of Products by Stage and Molecule Type, Hepatitis A 35
Table 23: Number of Products by Stage and Target, Hepatitis B 36
Table 24: Number of Products by Stage and Mechanism of Action, Hepatitis B 39
Table 25: Number of Products by Stage and Route of Administration, Hepatitis B 41
Table 26: Number of Products by Stage and Molecule Type, Hepatitis B 43
Table 27: Number of Products by Stage and Target, Hepatitis D 45
Table 28: Number of Products by Stage and Mechanism of Action, Hepatitis D 46
Table 29: Number of Products by Stage and Route of Administration, Hepatitis D 48
Table 30: Number of Products by Stage and Molecule Type, Hepatitis D 49
Table 31: Number of Products by Stage and Target, Hepatitis E 49
Table 32: Number of Products by Stage and Mechanism of Action, Hepatitis E 50
Table 33: Number of Products by Stage and Route of Administration, Hepatitis E 50
Table 34: Number of Products by Stage and Molecule Type, Hepatitis E 51
Table 35: Hepatitis A - Pipeline by Beijing Minhai Biotechnology Co Ltd 52
Table 36: Hepatitis A - Pipeline by Cadila Healthcare Ltd 52
Table 37: Hepatitis A - Pipeline by China National Pharmaceutical Group Corp 53
Table 38: Hepatitis A - Pipeline by Indian Immunologicals Ltd 53
Table 39: Hepatitis A - Pipeline by Sinovac Biotech Ltd 54
Table 40: Hepatitis B - Pipeline by Abivax SA 54
Table 41: Hepatitis B - Pipeline by AiCuris GmbH & Co KG 55
Table 42: Hepatitis B - Pipeline by AIMM Therapeutics BV 55
Table 43: Hepatitis B - Pipeline by Akshaya Bio Inc 56
Table 44: Hepatitis B - Pipeline by Alnylam Pharmaceuticals Inc 56
Table 45: Hepatitis B - Pipeline by Altimmune Inc 57
Table 46: Hepatitis B - Pipeline by Altravax Inc 57
Table 47: Hepatitis B - Pipeline by Amarna Therapeutics BV 58
Table 48: Hepatitis B - Pipeline by Arbutus Biopharma Corp 58
Table 49: Hepatitis B - Pipeline by Arcturus Therapeutics Ltd 59
Table 50: Hepatitis B - Pipeline by Arrowhead Pharmaceuticals Inc 59
Table 51: Hepatitis B - Pipeline by Ascentage Pharma Group Corp Ltd 60
Table 52: Hepatitis B - Pipeline by Assembly Biosciences Inc 60
Table 53: Hepatitis B - Pipeline by Aucta Pharmaceuticals LLC 61
Table 54: Hepatitis B - Pipeline by Beijing Kawin Technology Share-Holding Co Ltd 61
Table 55: Hepatitis B - Pipeline by Beijing Minhai Biotechnology Co Ltd 62
Table 56: Hepatitis B - Pipeline by Benitec Biopharma Ltd 62
Table 57: Hepatitis B - Pipeline by Biological E Ltd 63
Table 58: Hepatitis B - Pipeline by BioStar Pharmaceuticals Inc 63
Table 59: Hepatitis B - Pipeline by Biotron Ltd 64
Table 60: Hepatitis B - Pipeline by Bolder Biotechnology Inc 64

List of Figures
1.2 List of Figures
Figure 1: Number of Products under Development for Hepatitis A 9
Figure 2: Number of Products under Development by Companies, Hepatitis A 10
Figure 3: Number of Products under Development for Hepatitis B 12
Figure 4: Number of Products under Development by Companies, Hepatitis B 13
Figure 5: Number of Products under Development by Universities/Institutes, Hepatitis B 17
Figure 6: Number of Products under Development for Hepatitis D 27
Figure 7: Number of Products under Development by Companies, Hepatitis D 28
Figure 8: Number of Products under Development for Hepatitis E 30
Figure 9: Number of Products under Development by Companies, Hepatitis E 31
Figure 10: Number of Products by Stage and Routes of Administration, Hepatitis A 33
Figure 11: Number of Products by Molecule Types, Hepatitis A 34
Figure 12: Number of Products by Stage and Molecule Types, Hepatitis A 34
Figure 13: Number of Products by Top 10 Targets, Hepatitis B 35
Figure 14: Number of Products by Stage and Top 10 Targets, Hepatitis B 36
Figure 15: Number of Products by Top 10 Mechanism of Actions, Hepatitis B 38
Figure 16: Number of Products by Stage and Top 10 Mechanism of Actions, Hepatitis B 38
Figure 17: Number of Products by Routes of Administration, Hepatitis B 40
Figure 18: Number of Products by Stage and Routes of Administration, Hepatitis B 41
Figure 19: Number of Products by Top 10 Molecule Types, Hepatitis B 42
Figure 20: Number of Products by Stage and Top 10 Molecule Types, Hepatitis B 42
Figure 21: Number of Products by argets, Hepatitis D 44
Figure 22: Number of Products by Stage and Targets, Hepatitis D 44
Figure 23: Number of Products by Mechanism of Actions, Hepatitis D 45
Figure 24: Number of Products by Stage and Mechanism of Actions, Hepatitis D 46
Figure 25: Number of Products by Routes of Administration, Hepatitis D 47
Figure 26: Number of Products by Stage and Routes of Administration, Hepatitis D 47
Figure 27: Number of Products by Molecule Types, Hepatitis D 48
Figure 28: Number of Products by Stage and Molecule Types, Hepatitis D 49
Figure 29: Number of Products by Molecule Types, Hepatitis E 50
Figure 30: Number of Products by Stage and Molecule Types, Hepatitis E 51